 Anxiety, depression, sleep quality, attitudes toward death, posttraumatic growth, mindfulness, self-compassion, and overall quality of life will be assessed by participants self-report at baseline, the primary endpoint, and one month after the third experimental session in Stage 1, and at equivalent points in Stage 2. Additional assessments of depression and overall psychological functioning will be made by a blinded Independent Rater at these time points. A caregiver and individuals in close relationship to the study subject will also provide ratings of the subjects posttraumatic growth and mood. Symptoms, long-term benefits, and harms will be assessed again at 6 months and 12 months after the final experimental session. This study will provide an estimate of effect size based on response of psychological symptoms to MDMA-assisted psychotherapy. 